Celgene and Agios ally with Abbott on leukaemia diagnostic research

Celgene and Agios Pharmaceuticals have announced a new partnership with Abbott that aims to improve the diagnosis of acute myeloid leukaemia.

The work will focus on the development and commercialisation of companion diagnostic tests for Abbott's m2000 RealTime System that will be able to identify isocitrate dehydrogenase (IDH) mutations in acute myeloid leukaemia patients.

Celgene is currently developing enasidenib, an IDH2 mutant inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukaemia who have an IDH2 mutation, while Agios is working on an IDH1 mutant inhibitor called AG-120 for those with IDH1 mutations.

These mutations occur in approximately 20 percent of patients and could be a promising treatment target. The new test that Abbott will help to develop will make it easier to identify individuals who would be most likely to benefit from such a therapeutic approach.

Dr Han Myint, vice-president for global myeloid medical affairs at Celgene, said: "Molecular profiling is important to identify genomic mutations which may have prognostic and potential treatment implications for patients with acute myeloid leukaemia."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.